CTLA4 and melanoma: Vijayakumar et al. (2020) assessed the impact of various immunostimulatory combinations of lentogenic NDV and only NDV-mediated blockade of PD-L1 provided a survival benefit in a unilateral tumor model, with fewer mice exhibiting a CR than observed in our study, possibly due to our use of mesogenic NDV rather than lentogenic NDV. Interestingly, Vijayakumar et al. (2020) also found that systemic CTLA-4 blockade in addition to treatment with rNDV improved tumor rejection in the bilateral melanoma model.